Amylyx Pharmaceuticals, Inc. ((AMLX)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amylyx Pharmaceuticals, Inc. is conducting a Phase 1 clinical study titled Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, PK and PD of Antisense Oligonucleotide AMX0114 Administered to Adult Participants With Amyotrophic Lateral Sclerosis. The study aims to assess the safety and tolerability of AMX0114, an antisense oligonucleotide, in adults with amyotrophic lateral sclerosis (ALS), focusing on its pharmacokinetics and pharmacodynamics.
The intervention being tested is AMX0114, administered via intrathecal injection. AMX0114 is designed to target and reduce the levels of calpain-2, a protein associated with neuron degeneration, with the goal of slowing down neuron injury and death in ALS patients.
This interventional study employs a randomized, sequential intervention model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are all blinded. The primary purpose of the study is treatment-focused.
The study began on April 7, 2025, with an estimated completion date not yet specified. The latest update was submitted on August 4, 2025. These dates are crucial for tracking the study’s progress and potential data releases.
The market implications of this study are significant, as positive results could enhance Amylyx Pharmaceuticals’ stock performance and investor confidence. The study’s progress is particularly relevant in the competitive landscape of ALS treatments, where advancements can shift market dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.